Department of Planning and Budget 2017 Fiscal Impact Statement

1.	Bill Numbe	er: SB848					
	House of Orig	in 🗌	Introduced		Substitute		Engrossed
	Second House		In Committee		Substitute		Enrolled
2.	Patron:	Wexton					
3.	Committee:	Passed Both Houses					
4.	Title:	Naloxone; dispensing for use in opioid overdose reversal, etc.					

5. Summary: Allows a person who is authorized by the Department of Behavioral Health and Developmental Services to train individuals on the administration of naloxone for use in opioid overdose reversal who are acting on behalf of an organization that provides substance abuse treatment services to individuals at risk of experiencing opioid overdose or training in the administration of naloxone for overdose reversal provided they have obtained a controlled substances registration from the Board of Pharmacy. Dispensing to such person who has completed a training program on the administration of naloxone for opioid overdose reversal shall be (i) pursuant to a standing order issued by a prescriber, (ii) in accordance with protocols developed by the Board of Pharmacy in consultation with the Board of Medicine and the Department of Health, and (iii) without charge or compensation. The bill also provides that a person who dispenses naloxone shall not be liable for civil damages of ordinary negligence for acts or omissions resulting from the rendering of such treatment if he acts in good faith. In addition, it specifies that a person to whom naloxone has been dispensed pursuant to the provisions of the bill may possess naloxone and may administer naloxone to a person who is believed to be experiencing or about to experience a life-threatening opioid overdose.

6. Budget Amendment Necessary: No.

7. Fiscal Impact Estimates: Final.

8. Fiscal Implications: There is no fiscal impact to this legislation. The amended version of the bill changes the word "opiate" to "opioid", which has no fiscal implication.

9. Specific Agency or Political Subdivisions Affected: Department of Behavioral Health and Developmental Services; Board of Pharmacy.

10. Technical Amendment Necessary: No.

11. Other Comments: This bill is a companion to HB1453.